Clinical Trial Update: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for sotatercept in pulmonary arterial hypertension (PAH) has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2023-04-19